Skip to main content

Adma Biologics, Inc 8-K, filed Nov 4, 2026

Adma Biologics, Inc. (ADMA)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

Adma Biologics, Inc filed this 8-K on November 4, 2026.

ADMA Biologics reported 3Q 2026 total revenue of $141.1 million, up 5% year-over-year, and GAAP net income of $49.9 million, up 37%; it reiterated FY2026 revenue guidance of at least $530 million while increasing adjusted earnings expectations. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits